Apixaban for Extended Anticoagulation (APIDULCIS)

CLICCA QUI PER TRADURRE IN ITALIANO CON GOOGLE TRANSLATE

Sponsor: Arianna Anticoagulazione Foundation

Sommario: The study aims at optimizing the long-term and extended management of patients with a first episode of venous thromboembolism (proximal deep vein thrombosis with or without pulmonary embolism) (VTE). Patients at high risk of recurrence (with altered D-dimer test), who had received anticoagulation (whatever the drug used) for 12-15 months after the first episode of thrombosis, will be treated with Apixaban 2,5 mg x 2 for 18 months as extended treatment. Patients at low risk, with normal D-dimer test, will stop anticoagulation definitely.


TIPOLOGIA STUDIO

Interventistico

FASE

Fase 4


TRATTAMENTO


OBIETTIVO PRIMARIO

  • Misura: Number and rate of patients with confirmed recurrent VTE and VTE-related death (efficacy).
  • Tempo: From date of enrollment until the date of first documented event assessed up to 18 months
  • Descrizione: The occurrence of proximal deep vein thrombosis with or without pulmonary embolism (new or recurrent episode) wil be recorded in all patients
  • Misura: Number and rate of major Bleeding events (defined according to International Society on Thrombosis and Haemostasis guidelines (safety)
  • Tempo: From date of enrollment until the date of first documented event assessed up to18 months
  • Descrizione: Fatal bleeding; intracranial; intraspinal; intraocular; pericardial; intra-articular; intramuscular with compartment syndrome; retroperitoneal,; acute clinically overt bleeding will be recorded in all patients

OBIETTIVO SECONDARIO

  • Misura: Number of and rate of thromboembolic events
  • Tempo: From date of enrollment until the date of first documented event assessed up to 18 months
  • Descrizione: Transient ischemic attack (TIA), Stroke, Myocardial infarction will be recorded in all patients
  • Misura: Presence of severe post-thrombotic syndrome according to Villalta Score
  • Tempo: 18 months
  • Descrizione: Patient with deep vein thrombosis as index event will be evaluated, at the and of follow-up, applying Villalta score, commonly used to diagnose post-thrombotic syndrome in the subacute phase of thrombosis. The presence of venous ulcer of the leg or a score > of 15 points indicate the occurrence of severe post-thrombotic syndrome. The maximum score is 33. The score from 5 to 9 points indicate mild post-thrombotic syndrome and from 10 to 15 points indicate moderate post-thrombotic syndrome
  • Misura: Number and rate of non major bleeding complications
  • Tempo: From date of enrollment until the date of first documented event assessed up to18 months
  • Descrizione: In all patients will be recorded any sign or symptom of hemorrhage that does not fit the criteria for the definition of major bleeding but does meet at least one of the following criteria: 1)requiring medical intervention by a healthcare professional; 2) leading to hospitalization or increased level of care;3) prompting a face to face evaluation
  • Misura: Number and rate of dead patients (overall mortality)
  • Tempo: From date of enrollment until the date of first documented event assessed up to 18 months
  • Descrizione: VTE-related death; cardiovascular related-death; bleeding-related death; death for: cancer, infectious disease and unknown cause; sudden death will be recorded in all patients

CRITERI DI ELIGIBILITA'

  • Criteri di inclusione e esclusione

    Inclusion Criteria: - First unprovoked Venous Thromboembolic Event - Venous Thromboembolic events associated with one or more risk factors that are no longer present - Age older than 18 or younger than 75 years - Capacity to give written informed consent Exclusion Criteria: - A) Exclusion criteria regarding the index event - Events usually associated with low risk of recurrence - Deep vein thrombosis/ Pulmonary embolism occurred within 3 months from major surgery or major trauma - Isolated Distal deep vein thrombosis (thrombosis of calf veins) - Events associated with a very high risk of recurrence or occurrence of life-threatening recurrent events - Pulmonary Embolism episode with shock or life-threatening - Isolated pulmonary embolism with a systolic pulmonary artery pressure > 60 mmHg at presentation - Deep vein thrombosis/ Pulmonary embolism associated with active cancer, antiphospholipid syndrome or long-standing medical illnesses - More than one idiopathic event - Index venous thromboembolic event in different sites than deep veins of the lower limbs or pulmonary arteries B) Exclusion criteria present at the moment of patients' screening: - Age younger than 18 or older than 75 years - More documented unprovoked venous thromboembolic episodes - Pregnancy or puerperium - Severe post-thrombotic syndrome (≥ 15 points at the Villalta score) - Solid neoplasia or blood disease in active phase or requiring chemotherapy/radiotherapy - All the clinical conditions requiring prolonged treatment with Low Molecular Weight Heparin - Presence of overt, active chronic diseases (i.e. inflammatory bowel disease) - Known serious thrombophilic alterations: - deficiencies of natural anticoagulants (Antithrombin, Protein C, Protein S) - homozygosity for Factor V Leiden or Factor II G20210A mutations - double heterozygosity - Presence of antiphospholipid syndrome - Presence of vein cava filter - Concomitant conditions (such as atrial fibrillation) requiring indefinite anticoagulation - Severe cardio-respiratory insufficiency (NYHA 3 or 4) - Any absolute contraindications to anticoagulation treatment - Any other contraindications to Apixaban as per local SmPC - Life expectancy shorter than 1 year - Refuse interruption of anticoagulation to perform serial D-dimer assessment - Geographically inaccessible location - Inability or refusal to give consent


SESSO

Tutti


ETA' MINIMA

Età Minima: 18 Years
Età Massima: 75 Years


LUOGO

Daniela Poli
Firenze, 50134

REFERENTE PER INFORMAZIONI

Cristina Legnani, BSc, PhD
0039 051 2812339
c.legnani@fondazionearianna.org